Fractyl Health (GUTS) Cash & Equivalents (2023 - 2026)

Fractyl Health (GUTS) has 4 years of Cash & Equivalents data on file, last reported at $63.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 50.12% year-over-year to $63.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.2 million (up 50.12% YoY) and the FY2025 annual result came in at $81.5 million, up 20.86% from the prior year.
• Cash & Equivalents retreated to $63.2 million in Q1 2026, from $81.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $121.4 million in Q1 2024 to a low of $22.3 million in Q2 2025.
• A 4-year average of $69.6 million and a median of $72.6 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 103.15% — and 2025, when it sank 78.24%.
• Tracing GUTS's Cash & Equivalents over 4 years: stood at $33.2 million in 2023, then surged by 103.15% to $67.5 million in 2024, then rose by 20.86% to $81.5 million in 2025, then fell by 22.49% to $63.2 million in 2026.
• The last three Cash & Equivalents figures came in at $63.2 million (Q1 2026), $81.5 million (Q4 2025), and $77.7 million (Q3 2025), per Business Quant data.